S
Saraswati Sukumar
Researcher at Johns Hopkins University School of Medicine
Publications - 262
Citations - 28255
Saraswati Sukumar is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 77, co-authored 248 publications receiving 26027 citations. Previous affiliations of Saraswati Sukumar include Tufts University & Salk Institute for Biological Studies.
Papers
More filters
Journal ArticleDOI
Unpredicted central inversion in a sgRNA flanked by inverted repeats.
TL;DR: During the performance of CRISPR/Cas9 gene knock out, it was found that the central part of a sgRNA was inverted after transformation into Escherichia coli, and the inverted portion was found to be flanked by inverted repeats, and sealing of nicks inside the plasmid could correct the inversion.
Posted ContentDOI
Validation of a low-cost, carbon dioxide-based cryoablation system for percutaneous tumor ablation
Bailey Surtees,Sean Young,Yixin Hu,Guannan Wang,Evelyn McChesney,Grace Kuroki,Pascal Acree,Serena Thomas,Tara Blair,Shivam Rastogi,Dara L. Kraitchman,Clifford R. Weiss,Clifford R. Weiss,Saraswati Sukumar,Susan C. Harvey,Nicholas J. Durr +15 more
TL;DR: The design and feasibility of a low-cost cryoablation system using widely-available carbon dioxide as the only consumable is presented, which was applied to mammary tumors in an in vivo rat model and necrosis was verified by histopathology.
Book ChapterDOI
Regulation of Angiogenesis in Cancer and Its Therapeutic Implications
TL;DR: This chapter describes physiological and pathological angiogenesis and growth factors and microenvironmental influences that govern its initiation, promotion and inhibition.
Proceedings ArticleDOI
Abstract P4-08-08: HOXC10, a homeobox protein overexpressed in breast cancer, modulates the response to chemotherapy treatment.
TL;DR: This study shows that HOXC10, a homeobox protein previously shown to be regulated during the cell cycle and to have a positive effect on proliferation, is overexpressed in the majority of breast cancers.
Journal ArticleDOI
HOXA5-Mediated Stabilization of IκBα Inhibits the NF-κB Pathway and Suppresses Malignant Transformation of Breast Epithelial Cells.
Priya Pai,Guannan Wang,Wei Wen Teo,Diana Raez-Rodriguez,Kathleen L. Gabrielson,Balázs Győrffy,Bradley M. Downs,Akanksha Aggarwal,Saraswati Sukumar +8 more
TL;DR: Data suggest that HOXA5 suppresses malignancy in breast epithelial cells by blunting NF-κB action via stabilization of its inhibitor IκBα, providing new insights into the tumor suppressor functions of HOxA5.